Treatment of nasal inflammatory diseases with LYO HA-CL - SAP
In vitro characterization of physico-chemical properties, cytotoxicity, bioactivity of urea-crosslinked hyaluronic acid and sodium ascorbyl phosphate nasal powder formulation.
Article specifications
This original article was published in 2019 in Journal of Int J Pharm. (IF 2017: 3.862) by Italian specialists. The aim was to understand if lyophilized dry powder formulation consisting of urea-crosslinked hyaluronic acid (HA-CL) and sodium ascorbyl phosphate (LYO HA-CL – SAP) could be used as adjuvant treatment for nasal inflammatory diseases.
Results
The results suggest that HA-CL and SAP had anti-inflammatory activity and acted in combination to accelerate wound healing. Therefore, LYO HA-CL - SAP could be a potential adjuvant in nasal anti-inflammatory formulations.